Q4 2025 United Therapeutics Corp Earnings Call Transcript
Key Points
- United Therapeutics Corp (UTHR) announced a revolutionary product, Tresmi, a soft mist inhaler that significantly reduces coughing, a common side effect of dry powder inhalers.
- The company reported record-breaking revenue for 2025, surpassing $3 billion for the first time, with a 7% growth in the fourth quarter compared to the previous year.
- UTHR is optimistic about the unblinding of their outcome study, which could lead to a new era of once-a-day treatments for pulmonary hypertension.
- The company is confident in the results of their TETON 2 study for IPF and expects similar positive outcomes from the TETON 1 study.
- UTHR is engaged in fruitful discussions with pharmaceutical companies interested in their AI-enabled digital lung model, which can predict pulmonary trial outcomes efficiently.
- The earnings call experienced technical difficulties, causing interruptions and potential miscommunication during the presentation.
- There is uncertainty regarding the impact of competitors like Liquidia on UTHR's market share, particularly concerning patient starts and referrals.
- The company acknowledges that sales can vary due to seasonal trends and the timing of orders, which may not accurately reflect patient demand.
- Despite strong revenue growth, UTHR's patient starts have lagged due to typical Q4 seasonality and severe weather conditions affecting sales.
- The company faces risks and uncertainties related to the approval and commercial launch of new products, which could impact future revenue projections.
Good morning, everyone and welcome to the United Therapeutics Corporation fourth-quarter 2025 corporate update conference call. My name is Jamie and I'll be your conference operator today. (Operator Instructions) Please also note today's event is being recorded. At this time, I'd like to turn the webcast over to Harry Silvers, Investor Relations Manager at United Therapeutics.
Thank you, Jamie. Good morning. It is my pleasure to welcome you to the United Therapeutics Corporation fourth quarter 2025 corporate update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements.
Today's remarks may discuss the progress and results of clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
